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Mononuclear phagocytes have been  increasingly recognized as  a  source of 
many of the complement proteins (1, 2). Activities constituting the intact com- 
plement alternative pathway in serum (factor B, factor D, C3, and properdin) 
(3-8), as well as the regulatory proteins, factors H and I (5, 8), are produced by 
mouse peritoneal macrophages and human peripheral blood monocytes. Factors 
C2 and C4 are also synthesized by mononuclear phagocytes (1, 2, 5, 9-11). 
Factor  B,  a  glycoprotein  of Mr  ~0.3,000  that  plays  a  central  role  in  the 
alternative pathway of complement activation (12,  13), is closely associated with 
the immune response as a class III gene product of the major histocompatibility 
complex in mice (14, 15), guinea pigs (16), and humans (17). Activated factor B 
(Bb, Mr ~60,000) serves as a migration inhibiting factor (18),  inducing macro- 
phage and monocyte spreading (19, 20) and possibly stimulating cytotoxic (21, 
22) and bacteriocidai activities (23, 24) of monocytes in vitro. 
The hemolytic activity of factor B produced by resident mouse peritoneal 
macrophages (3, 6) increases linearly during 72-96 h in culture, and its synthesis 
is regulated by lipopolysaccharide (LPS) 1 (24).  In contrast, a  48-72  h  lag has 
been observed (5, 7) before synthesis of factor B is initiated by human peripheral 
blood  monocytes in  culture,  and  there  are  differences in  synthesis  between 
monocytes and  tissue  macrophages  (9,  10)  correlating  with  the  recognized 
maturation of human peripheral blood monocytes into macrophages (25). The 
molecular sizes  and  chain composition of the cellular and  secreted forms of 
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human factor B produced by monocytes and hepatoma cells are similar to those 
of factor B purified from serum (7,  25-27).  The high molecular weight forms 
of cellular factor B antigens that have been described (27) may be artifactual. 
In response to developmental and environmental signals, mononuclear phag- 
ocytes  display  a  variety  of  functional  states  characterized  by  differences  in 
morphology, surface antigens, and  protein  secretion.  Whereas some proteins, 
such as lysozyme, are  secreted constitutively, others,  such as apolipoprotein  E 
(ApoE), vary according to the inflammatory state of the macrophage (28). 
In this report we show that the major constitutive Mr 90,000-93,000  glyco- 
protein synthesized and secreted by mouse peritoneal macrophages is factor B, 
and that this protein is active in the complement system. In addition, we have 
compared  the conditions under  which  ApoE  and  factor B  are  synthesized by 
macrophages. 
Materials and Methods 
Human Complement Proteins and Antibody to Human Complement Factor B.  We prepared 
human complement proteins factor B (29),  factor Bb (20,  29), factor D (30), and cobra 
venom factor (CVF) (31) as described previously. Factor B was radiolabeled with 1~5I by 
the method of Bolton and Hunter (32), and factor Bb was labeled by the Iodogen (Pierce 
Chemical Co., Rockford, IL) method of Fraker and Speck (33). Specific rabbit antibody 
directed against factor B was prepared by affinity chromatography on Sepharose (CNBr- 
Sepharose; Pharmacia Fine Chemicals, Piscataway, NJ) containing covalently bound factor 
B antigen. Adsorbed Ig were eluted with 0.1  M acetate-buffered, 0.14 M saline, pH 2.5, 
containing 0.02 M EDTA, into 0.2 M Tris-buffered 0.14 M saline, pH 8.0. 
Preparation  of Mouse Plasma.  We collected normal mouse plasma from ICR mice by 
retroorbital puncture into citrate phosphate dextrose at a final citrate concentration of 
20 raM. Phenylmethylsulfonyl fluoride (PMSF) was added as a proteinase inhibitor at a 
final concentration of 5 mM. This normal mouse plasma was stored at -70°C until used. 
Alternatively, normal mouse plasma frozen in acid citrate dextrose was purchased from 
Pel-Freez Biologicals, Rogers, AR, and PMSF was added to a final concentration of 5 mM 
when the sample was thawed. We also collected fresh normal mouse plasma from BALB/c 
mice by cardiac puncture. 
Purification  of Mouse  Factor Bb.  We purified mouse factor Bb from normal mouse 
plasma by affinity chromatography on a 2 ml CNBr-Sepharose column containing 1 mg 
of affinity-purified anti-human factor B Ig. Mouse factor B was eluted with glycine-HC1 
buffer, pH 2.5, into Tris-HCI, pH 8; 106 +  16/zg (mean -+ SD; n = 4) of factor B antigen 
was isolated per milliliter of normal mouse plasma. Assuming a factor B concentration of 
160 #g]ml in this plasma (as measured by radioimmunoassay [RIA]), the apparent recovery 
of protein in this step was 62 +  3% (n -- 4) by this column chromatographic method. We 
analyzed mouse factor B  by nonreducing sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) (34). 
Factor B RIA.  We developed a double-antibody equilibrium RIA specific for factor B. 
Human factor B (50 #g) was radiolabeled with 1 mCi ~25I-labeled Bolton-Hunter reagent 
(32) (Amersham Corp., Arlington Heights, IL) to a final specific activity of 6-9  ×  105 
cpm/#g. Over 90% of radiolabeled factor B was precipitated with 10% trichloroacetic 
acid; >95% of cpm were Mr 90,000, as assessed by SDS-PAGE (6% acrylamide) (35), and 
>90% of cpm had a sedimentation rate of 5-6 S, as assessed by sucrose density gradient 
ultracentrifugation. Dilutions of all reactants were made in 0.1 M Tris-HCI, 0.14 M NaCl, 
pH 7.2, containing 2% heat-inactivated normal rabbit serum. The assay consisted of three 
compartments: (a) 250 #1 t~5I-labeled factor B (0.5 nM); (b) 250 #1 affinity-purified  rabbit 
anti-factor B Ig (diluted 1:1500); and (c) 250 ul of a competitor. After 18 h at 4°C, 250 
el of goat anti-rabbit Ig was added, and allowed to react for 5 h at 4°C. The immunopre- 308  MOUSE  MACROPHAGES SECRETE FACTOR  B CONSTITUTIVELY 
cipitates formed were removed by centrifugation (I ,200 g for 30 min), and an aliquot of 
the  supernatant  (750 ~l)  was  removed and  counted to determine (by difference) the 
radioactivity bound in the immunoprecipitate. 
Mouse Peritoneal Macrophages.  We collected macrophages by lavage from the perito- 
neal cavities of CD-1, C3H/HeN (Charles River Breeding Laboratories, Inc., Wilmington, 
MA), and C3H/HeJ (The Jackson Laboratory, Bar Harbor, ME) strains of mice injected 
12 d  previously with  2-6 x  106 viable mycobacteria of strain bacillus Caimette-Guerin 
(BCG), or 4 d previously with 1 ml of Brewer's thioglycollate broth (Difco Laboratories, 
Detroit, MI),  25 mg/kg of pyran copolymer (a gift of Hercules Inc., Wilmington, DE), 
0.5 ml of 5 mM NalO4,  10-30/~g of detoxified LPS from Salmonella typhimurium, or 1 
mg Corynebacterium parvum  (RIBI  Immunochem,  Hamilton,  MT) (36,  37).  We plated 
macrophages at a density of 5 ×  10  s cells in 2 cm  ~ in Dulbecco's modified Eagle's medium 
supplemented with  10% heat-inactivated (56°C, 30 min) fetal bovine serum (FBS) for 2 
h at 37°C in an atmosphere of 95% air and 5% CO2. Nonadherent cells were removed 
by  washing,  and  adherent  cells were  placed  in  serum-free  medium  containing  0.2% 
lactalbumin hydrolysate. We prepared macrophage cellular extracts by washing the cell 
monolayer three times with 0.15  M  NaCI and then scraping, in the presence of 0.1% 
Triton X-100, to remove cells.  We stored lysates and medium samples at -20°C  until 
used. 
Mouse Bone Marrow-derived  Macrophages.  We flushed cells from mouse femurs with 
Hanks'  balanced salt solution, then grew  them  in medium containing  10%  FBS,  10% 
horse serum, and 10% L cell-conditioned medium (38, 39). The mouse macrophage line 
P388D 1 was cultured as described previously (39). 
Radiolabeling of Proteins.  We incubated macrophages with [35S]methionine,  and ana- 
lyzed secreted and cellular proteins by SDS-PAGE using the Laemmli buffer system (34, 
36, 40). For radiolabeling of secreted macrophage serine esterases, we treated conditioned 
medium (CM) from thioglycollate-elicited macrophages with [3H]diisopropyifluorophos- 
phate (DFP) (New England Nuclear, Boston, MA), essentially as described previously (41). 
lmmunoprecipitation  of Factor B from  Mouse Macrophages.  Radiolabeled proteins  in 
macrophage-conditioned medium or cell lysates were immunoprecipitated according to a 
modification (36,  41) of the Jones procedure (42).  Briefly, we prepared cell lysates by 
scraping  cells  into  phosphate-buffered saline  containing  0.5%  Nonidet  P-40,  2  mM 
methionine, and 0.02% NaNs (SAC buffer). CM was centrifuged to remove any cellular 
debris before preadsorption for 15 min on ice with 60 #g of rabbit anti-bovine serum 
albumin (anti-BSA) IgG (Cappei Laboratories, Cochranville, PA) per milliliter of sample 
and 150-200 #1 of 10% Staphylococcus aureus suspension (Zysorbin; Zymed Labs, Burlin- 
game, CA). The Zysorbin had been washed three times in SAC buffer, and resuspended 
in  SAC  buffer containing  1  mg/ml  of ovalbumin.  We  then  immunoprecipitated the 
preadsorbed  samples  for  30  min  at  25°C  with  10  #g  rabbit  anti-human  factor B. 
Nonimmune IgG was used as a control. After immunoprecipitation, we added 200 #! of 
S. aureus suspension and allowed it to react for 20 min on ice. We centrifuged the samples 
and washed the pellets twice with SAC-ovalbumin buffer, once with SAC buffer, then 
resuspended them in  Laemmli sample buffer, and boiled them in a water bath before 
electrophoresis. ApoE was identified by immunoprecipitation, and fibronectin was iden- 
tified by binding to S. aureus (36). Factor B in macrophage secretions was also identified 
by immunoblotting onto nitrocellulose filters (43) essentially as described previously for 
ApoE (36). 
Conditions for Activation of Macrophage Factor B.  We studied the functional properties 
in the complement system of mouse macrophage factor B by testing for the ability of the 
protein to form a  complex with  CVF,  in  which  factor B  is cleaved by factor D.  We 
incubated samples of media or cell extracts (100 #1) for 60 min at 37°C with 10 #g CVF, 
16 #g of factor D, 4 mM MgCI2, and 0.02 mM CaCI~. After this incubation, we precipitated 
activated factor B antigens from the incubation mixture by rabbit anti-human factor B, 
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Results 
Purification of Mouse Plasma Factor Bb.  Mouse plasma factor B exhibited two 
or three polypeptides with apparent Mr of 60,000-65,000  under nonreducing 
conditions in SDS-PAGE; these polypeptides comigrated with human factor Bb 
produced by activation of purified factor  B  with  C3b  and factor  D  (Fig.  1). 
Under reducing conditions, with dithiothreitol, both mouse and human factor 
Bb migrated in SDS-PAGE as a  single polypeptide species, suggesting that the 
three  bands  observed  under  nonreducing  conditions  may  be  due  to  slight 
heterogeneity in either the detergent binding or polysaccharide composition of 
Bb. The size of the polypeptides indicates that mouse factor Bb, and not native 
factor B, is the primary product of this purification procedure. 
In the factor B RIA, purified factor B and normal human serum competed 
with a typical dose response (Fig. 2 a). Purified factor D, C3, C5, human albumin, 
or serum immunochemically depleted of factor B did not compete, indicating 
the specificity of the assay (data not shown). The cross-reaction of mouse factor 
B with antibody to human factor B is shown in Fig. 2b. At a dilution of 1:96, 
normal  mouse plasma  inhibited the binding of anti-human  factor  B  to  ~25I- 
labeled factor B to a maximum of 10-15% (Fig. 2 b). We calculated the apparent 
concentration of factor B antigen in normal mouse plasma to be 120-180 #g/ml 
(in  human factor  B antigenic equivalents).  FBS,  calf serum,  goat serum, and 
normal rabbit serum containing hemolytically active factor B did not significantly 
compete with human factor B at dilutions of 1:50 to 1:500 (<4% inhibition). 
Identification of  Factor B as a Major Protein Secreted by Mouse Macrophages.  The 
CM from BCG-elicited macrophages incubated with [35S]methionine contained 
two prominent, newly synthesized polypeptides migrating as a  doublet of Mr 
90,000 and 93,000 in SDS-PAGE. They were identified as complement factor B 
by their comigration with purified human serum factor B, immunoprecipitation 
with affinity-purified antibodies from antisera raised to human factor B, Western 
immunoblotting, and mapping of the products of partial digestion with chymo- 
trypsin (Fig. 3). In addition, factor B is a serine proteinase that is weakly labeled 
after  incubation  with  [3H]DFP  (44).  When  macrophage-conditioned culture 
medium was incubated with  [SH]DFP  and  then analyzed by  SDS-PAGE,  the 
prominent Mr 90,000  macrophage polypeptide was weakly labeled with [3H]- 
DFP, although there was strong labeling of many other polypeptides (data not 
FIGURE  1.  Comparison of 6% SDS-PAGE of purified mouse factor Bb (3 and 4) with purified 
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FIGURE 9.  (a) Characteristics ofa competitive equilibrium double-antibody RIA for factor B 
using 0.5 nM l~sI-labeled human factor B, rabbit anti-human  factor B, and goat anti-rabbit 
Ig. (D) Factor B competitor; (0) normal human serum competitor. (b) Antigenic cross-reactions 
between (,) purified mouse factor Bb, (A) factor B in normal mouse plasma, and (B) human 
factor g using the competitive equilibrium R|A for human factor B. 
shown).  Thioglycollate-elicited  macrophages  were  collected  by  lavage  of the 
peritoneal cavity, and  immediately placed  in  suspension  with  [~SS]methionine. 
Synthesis and  secretion  of factor  B  were  detectable  by  immunoprecipitation, 
remaining at the same rate for the first 6  h  in culture (data not shown).  Factor 
B was first detected in the medium of thioglycollate-elicited macrophages after 
30-60  rain  of continuous  radiolabeling,  reaching a  constant  rate  of secretion 
after  2  h,  remaining  linear  for ~6  h,  and  still  increasing  after  24  h  (Fig.  4). 
Factor  B  represented  ~0.5%  of total  cellular protein  synthesized at  0.5  h  of 
labeling. Intracellular factor B reached a plateau after 3-4 h of labeling and then 
remained constant at about the  level of factor B  secreted in  a  2  h  period.  In SUNDSMO ET  AL.  311 
FIGURE 3.  (a) Immunoprecipitation of factor B from CM of BCG-elicited  macrophages. Cells 
(108) were incubated with 25 gCi/ml [sSS]methionine for 19 h, and secreted proteins were 
analyzed by SDS-PAGE. B, ~51-1abeled  factor B standard, showing B, Bb, and Ba components; 
CM, trichloroacetic acid precipitate of 50 #1 of CM; CM-IP, immunoprecipitate of factor B 
from 500 #i of CM by rabbit anti-human factor B; C-IP, control immunoprecipitate of CM by 
rabbit anti-BSA lgG.  Molecular weight markers are indicated at the left. (b) Chymotryptic 
peptide maps of factor B from the MT 93,000 band from factor B standard (B) and the Mr 
93,000 and 90,000 bands from the immunoprecipitate from macrophage secretions (CM-IP). 
(c) Western immunoblot of factor B from resident macrophages. CM, fluorogram of trichlo- 
roacetic acid precipitate of 100 #1 of CM from [sSS]methionine-labeled  cells; W, immunoblot 
of factor B from the same CM. 
pulse-chase experiments, after 30 min of incubation with [SSS]methionine, factor 
B appeared in the medium with a  half-time of 60 min. 
Effect  of Inflammatory  Stimuli  on  Cellular and  Secreted  Factor  B.  Peritoneal 
macrophages elicited by various inflammatory agents  differ in  their metabolic 
and functional activities (36,  37,  45-47).  Nonspecifically elicited and immuno- 
logically activated  peritoneal  macrophages  display  distinct  patterns  of protein 
secretion  immediately  after  explanting,  and  some  differences are  maintained 
after culture for several days (36).  However, newly synthesized factor B  was a 
constant proportion of the total secreted proteins from 2  to 72 h  in culture, and 
did not significantly differ in thioglycollate-, NaIO4-, BCG-, or pyran copolymer- 
elicited macrophages (Table I). The amount of factor B in the cell extracts and 
culture  medium  of mouse  macrophages  elicited  by  a  variety  of stimuli  was 
quantified by equilibrium RIA (Tables II and III). The cell lysates contained 2- 
4  nmol factor B per 5  x  105 cells (Table II), and medium samples contained 2- 312  MOUSE  MACROPHAGES  SECRETE  FACTOR  B  CONSTITUTIVELY 
FIGURE 4.  Appearance of factor  B  in  cell  extracts and  medium  of thioglycollate-elicited 
macrophages during continuous labeling. Cells were plated for 2  h,  washed,  and incubated 
with 25 #Ci/ml [35S]methionine for the times indicated. Medium was either acid-precipitated 
(CM) or immunoprecipitated (CM-IP) by rabbit anti-human factor B or by rabbit anti-BSA 
IgG. Cell lysates were treated in the same manner. The factor B band and molecular weight 
markers are indicated. 
10 nM factor B (Table III). Medium obtained from P388D1, a continuous mouse 
macrophage cell line, contained similar amounts of factor B antigen; however, 
medium from  L  cells  (a  continuous  fibroblast  cell  line)  contained  <0.01  nM 
factor B (Table III). 
Activation  of Macrophage  Factor  B  to  Factors Bb  and  Ba.  The  complement 
system activity of the prominent biosynthesized factor B (Mr 90,000 and 93,000) 
polypeptides in CM was investigated by studying conversion of factor B to factor 
Bb (M,. 60,000-65,000)  and Ba (Mr 30,000-38,000)  activation fragments. [35S]- 
Methionine-labeled secretion products of thioglycollate-elicited or BCG-activated 
peritoneal  macrophages  were  incubated  with  CVF,  factor  D,  and  Mg+÷;  and 
factor  B  was  immunoprecipitated by affinity-purified antibody against  human 
factor B. SDS-PAGE showed biosynthetically labeled molecular species of appar- 
ent Mr  93,000,  90,000,  65,000,  63,000,  60,000,  38,000,  36,000,  and  30,000 
(Fig. 5).  These polypeptides were not precipitated by nonimmune serum or by SUNDSMO  ET  AL. 
TABLE  I 
Effect of Inflammatory Stimuli on the Rate of lncorporation of [SSS]  - 
Methionine Into Secreted  Factor B of Macrophages after Various 
Times in Culture 
Secreted factor 
B  Time in 





2  6.7 
48  4.5 
72  4.3 
NalO4  2  4.4 
48  6.5 
72  4.2 
BCG  2  6.8 
48  6.7 
72  6.8 
Pyran copolymer  2  5.4 
48  5.3 
72  5.7 
Elicited macrophages  (5 x  10  s cells/well) were cultured for 2-72 h, and 
secreted factor B was determined by densitometry of fluorograms of SDS- 
PAGE of secreted proteins from macrophages incubated with [sSS]methi- 
onine for 2 h. 
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TABLE  II 
Concentration of Factor B in Lysates  of Elicited Peritoneal 
Macrophages as Measured by RIA 
Time in  Factor B concentration per 5 × 
Eliciting agent  culture  105 cells 
Thioglycollate 
h  nmol  ng 
2  2.8 -+ 0.8  176 
24  2.5_ 1.1  158 
BCG  2  3.6 +  1.5  227 
24  4.1 +  1.8  258 
Elicited macrophages (5 x  l0  s cells/well) were cultured for 2 or 24 h, and 
lysates were prepared. Five dilutions of each of duplicate  samples were 
assayed in the factor B RIA. Data are expressed in equivalents of human 
factor B (mean + SD). 
an  unrelated  antigen-antibody  system,  BSA/anti-BSA.  The  prominent  Mr 
90,000-93,000  immunoprecipitable  radiolabeled polypeptides were significantly 
reduced  after  incubation with  CVF,  factor  D,  and  Mg  ÷+,  with  concomitant 
increases in the labeling of Mr 60,000-65,000  and Mr 30,000-38,000  polypep- 314  MOUSE  MACROPHAGES  SECRETE  FACTOR  B  CONSTITUTIVELY 
TAnLE  III 
Accumulation of Factor B in the CM of Macrophages,  as Measured by 
RIA 
CM collection 
Macrophage source  time  Factor B concentration 
h  nM  ng/ral 
Resident  48  2.4 +  2.3  151 
BCG-elicited  48  1.1  _+ 0.6  69 
LPS-elicited  24  10.8 _  1.1  680 
C. parvum-elicited  48  10.0 _+ 0.0  610 
P388D1  24  2.9 -+ 2.5  183 
L cell fibroblasts  24  <0.01  <0.6 
Macrophages (5-10 x  l0  S cells/well) were cultured for 24 or 48 h in 1 ml 
of serum-free medium; for  the peritoneal macrophages,  this began  2  h 
after explanting into culture. Macrophages were obtained from either CD- 
1 or C3H/HeN  mice. Each type of culture, in duplicate or triplicate, was 
assayed  at  three  dilutions in  the  factor  B  RIA.  Data  are  expressed  in 
equivalents of human factor B (mean +  SD). 
FIGURE 5.  Activation of factor B from CM of BCG-activated (BCG) or thioglycollate-elicited 
(THIO) macrophages. Cells were incubated with [sSS]methionine, and secreted proteins were 
acid-precipitated, immunoprecipitated by rabbit anti-human factor B, or activated by incu- 
bating 100-#l samples as described in Materials and Methods. Samples were then analyzed by 
SDS-PAGE.  Molecular  weight  markers  are  indicated  at  the  left.  (1)  Trichloroacetic  acid 
precipitate of 50 #l of CM; (2) trichloroacetic acid precipitate of 280 #l of activated CM; (3) 
immunoprecipitate of factor B from 500 #1 of CM; (4) immunoprecipitate of factor B from 
280 #1 of activated CM; (5) control immunoprecipitate of 500 #l of CM by rabbit anti-BSA 
IgG; (6,  7)  immunoprecipitate of 12SI-labeled  factor  B and  Bb standards; (8,  9)  lsSI-labeled 
factor B and Bb standards; (10) activated z~SI-labeled factor B. SUNDSMO  ET  AL.  315 
tides. These molecular sizes correspond to the sizes of purified factor Bb (Fig.  1) 
and Ba activation fragments. 
Distinct Phenotypes  for the Synthesis and Secretion of Factor B, ApoE, and Fibro- 
nectin by Macrophages in Culture.  Thioglycollate-elicited macrophages synthe- 
sized and secreted detectable factor B, ApoE, and fibronectin at 2 and 72 h of 
culture (Fig. 6). In contrast, macrophages elicited with pyran copolymer synthe- 
sized only factor B at 2 h, and synthesized ApoE after culture for 72 h, while 
their secretion of factor B decreased somewhat. They did not synthesize fibro- 
nectin (Fig. 6). 
During the culture of bone marrow-derived cells in the presence of L cell- 
conditioned medium, mononuclear phagocyte precursors  serially express  the 
differentiated properties of monocytes and macrophages, including protein se- 
cretion (39).  Secretion of factor B was detectable by day 5, and remained at 
approximately the same relative rate  through  day  14  of culture (Fig.  7).  In 
contrast, ApoE secretion did not commence until day 9 (Fig. 7) (39). Thus, factor 
B expression appears relatively early during the development of these cells from 
bone marrow precursors,  and  is  constitutive by the  monocyte and  immature 
macrophage stages. 
Modulation of  Macrophage Factor B Secretion by LPS.  There is evidence, based 
on hemolytic  assays, that macrophage factor B activity is increased after treatment 
FIGURE 6.  Comparison of factor B (B), ApoE (E), and fibronectin (FN) synthesis by thiogly- 
collate-elici'ted (THIO) and pyran copolymer-elicited (PYRAN) macrophages in culture for 2 
or 72 h.  Fibronectin was identified as the Mr 240,000 band binding to S. aureus precipitates. 
(1) Trichloroacetic acid precipitate of CM from 1.25 X 105 macrophages; (2) immunoprecipi- 
tate of fibronectin plus ApoE from CM of 2 x  105 macrophages by rabbit anti-rat ApoE IgG; 
(3) immunoprecipitate of factor B from CM of 2 x  10  s macrophages; (4) control immunopre- 
cipitate with rabbit anti-BSA lgG of CM. 316  MOUSE  MACROPHAGES  SECRETE  FACTOR  B CONSTITUTIVELY 
FIGURE 7.  Secretion  of factor  B during culture of bone marrow-derived macrophages. 
Mouse bone marrow macrophages were cultured in Dulbecco's modified Eagle's medium plus 
10% FBS supplemented with 10% horse serum and 10% L cell-conditioned  medium for 5, 7, 
9,  12, or  14 d. The media were then acid-precipitated  (BONE MARROW) and analyzed on 
SDS-PAGE. CM from thioglycollate-elicited macrophages (CM) was also acid-precipitated  (7) 
and factor  B immunoprecipitated (lP) for comparison.  Factor B standard (B) shows both Mr 
93,000 and 68,000 bands. ApoE is the secreted protein seen at Mr 33,000 (arrow). Molecular 
weight markers are indicated. 
TABLE  IV 
Effect of LPS on Accumulation  of Factor B in the CM of Resident 
Peritoneal Macrophages 
LPS  Ratio of  Factor B concentration  concentration  treated/control 
ng/ml  nM  ng/ml 
0  0.6 ± 0.1  38  1 
1  1.2 4- 0.6  75  2 
10  1.2 + 0.0  75  2 
100  6.5 + 0.7  409  11 
Resident  peritoneal macrophages  (5  ×  105 cells/well) from  C3H/HeN 
mice were placed in serum-free  medium containing 0-100 ng/ml of LPS 
for 24 h, in duplicate to quadruplicate cultures. Each medium sample was 
assayed at three dilutions in the human factor B RIA. Data are expressed 
in equivalents of human factor B (mean 4- SD). 
of cells with LPS (24).  In the present study, injection of mice with LPS yielded 
macrophages with increased secretion of factor B  into the medium (Table III). 
In addition, LPS added directly to cultures of macrophages increased production 
of factor B by as much as  11-fold at 100 ng/ml, as measured by RIA (Table IV). SUNDSMO  ET  AL.  317 
Treatment of macrophages from the endotoxin-resistant C3H/HeJ mouse strain 
(37) in culture with as much as 10 #g/ml of LPS increases factor B accumulation 
by less than twofold. In contrast, LPS decreases ApoE secretion (37). 
Discussion 
Our data indicate that the major Mr 90,000-93,000 polypeptides synthesized 
by mouse macrophages in culture are factor B of the complement system. This 
glycoprotein is recognized to be the serine proteinase active in the alternative 
pathway of complement  activation. The Bb activation fragment is, as has recently 
been  shown,  biologically active  in  inducing macrophage spreading (19,  20), 
intracellular killing (22,  23),  and lymphocyte blastogenesis (48).  Macrophages 
may also bind factor B to their surfaces (49). The results presented here provide 
physical evidence and quantitative data that confirm and extend earlier obser- 
vations, based largely on measurements of hemolytic activity, that factor B is 
synthesized by macrophages (4-6, 24, 27). Our findings also indicate that a large 
percentage of factor B synthesized by macrophages is hemolytically active in the 
complement system, because biosynthetically radiolabeled factor B was cleaved 
after the addition of purified CVF, factor D, and Mg  ÷+. 
Several  lines of evidence support these conclusions. First,  the radiolabeled 
polypeptides of Mr 60,000-65,000 and 30,000-38,000, sometimes detected in 
immunoprecipitates from macrophage extracts and culture medium, may be the 
endogenous factor B activation fragments, factor Bb and factor Ba, respectively. 
Antibody prepared to factor B specifically precipitated biosynthetically labeled 
polypeptides of Mr 90,000-95,000,  60,000-65,000,  and 30,000-38,000  from 
the medium and cellular extracts of mouse macrophages. Second, biosynthetically 
labeled Mr  90,000  and  93,000  polypeptides in  macrophage culture  medium 
decreased after complement activation in the medium by the addition of CVF 
and purified factor D, with a concomitant increase in the smaller Mr 60,000- 
65,000 CBb-like") and Mr 30,000-38,000 ("Ba-like")  activation fragments. Im- 
munochemical comparison by RIA of macrophage-associated factor B antigens 
and purified factor B showed that these polypeptides share common epitopes, 
indistinguishable in RIA analyses. The finding that the P388D 1 macrophage cell 
line synthesized factor B while cultured in serum-free medium adds additional 
support to the interpretation that factor B is a biosynthetic product of macro- 
phages and not of some other possible contaminating cell type. Finally, factor B 
accumulated in the CM of mouse macrophages to 10 nM (600 ng/ml) and was 
present in cell extracts at 4-8 nmol/106 cells, as determined by RIA. 
Resident macrophages and macrophages elicited with the nonspecific inflam- 
matory agent,  thioglycollate, synthesize ApoE,  but  those elicited with  pyran 
copolymer do not, suggesting that synthesis of ApoE is repressed during cellular 
activation (36). In contrast, factor B was synthesized, secreted, and accumulated 
in the medium of resident peritoneal macrophages, macrophages elicited with 
thioglycollate, and macrophages activated with pyran copolymer or BCG. We 
found no significant difference in the concentration of factor B in the medium 
at 24 or 48 h  when peritoneal macrophages were collected from mice injected 
with thioglycollate, BCG, LPS, or C. parvum. Factor B was also present in the 
medium of mouse bone  marrow-derived mononuclear phagocytes at  5  d  in 318  MOUSE  MACROPHAGES  SECRETE  FACTOR  B  CONSTITUTIVELY 
culture, an early monocytic stage in their maturation, whereas ApoE secretion 
began only after 9 d. These data suggest that factor B is a constitutive product 
of macrophages.  However,  the  synthesis of factor B  could  be  modulated by 
certain  signals,  because  treatment  of macrophages  with  LPS  resulted  in  an 
increase  both  in  synthesis  rate  and  in  the  concentration  of factor  B  in  the 
medium. We also noted that, after 72  h  in  culture, macrophages activated in 
vivo by BCG and pyran copolymer decreased their rates of secretion of factor B 
as their activated state was lost (36). This is in keeping with a recent observation 
that "r-interferon stimulates factor B synthesis (Z. Werb, unpublished data). 
Although these experiments have established that the proenzyme factor B is 
secreted in prodigious amounts by macrophages, the immunoprecipitation pat- 
terns suggest that conversion of factor B to the active form, Bb, occurs slowly, if 
at all,  in  culture,  raising  questions about  the events that  may be required to 
activate macrophage-derived factor B to Bb. The cellular proteinases mediating 
activation of factor B are, at present, unknown; however, trypsin (59), plasmin 
(30), kallikrein (51), and factor D (in the presence of C3b) (30) have been shown 
to cleave and activate factor B in an experimental system of purified proteins. 
Because factor D and C3 are synthesized by macrophages (1, 2, 4,  5), and C3b 
is associated with lymphocytes (52), it is possible that these proteins and cells may 
act cooperatively to activate macrophage-derived factor B. 
To assess the possible biological significance of macrophage-derived factor B, 
the relative amount of factor B synthesized by macrophages was quantified. In a 
previous study (20), activated factor Bb induced macrophage spreading at con- 
centrations  of  1-30  nM  in  culture  medium.  In  the  present  study,  factor  B 
constituted 4-6% of the total biosynthetically labeled protein secreted by mac- 
rophages. Cellular and secreted factor B concentrations, measured by RIA, were 
well within this range of potential biological activity; however, it is important to 
note that the extent of activation of factor B to  Bb in  these cultures was not 
determined. Although factor Bb is significantly less active in cleaving C3 and C5 
after release from the C3b-Bb complex (53), free factor Bb also retains a limited 
ability to cleave C3 and C5 in the absence of C3b (54). These combined findings 
make it difficult, at present, to assess what biological role factor B may play in 
macrophage cultures. 
It is unlikely that factor B plays a  major role as a  macrophage plasminogen 
activator (55), because the properties of macrophage plasminogen activator (40, 
56) are not similar to those of factor B.  Synthesis of plasminogen activator is 
induced when macrophages are elicited with thioglycollate or BCG (35, 40, 56), 
whereas synthesis of factor B was constitutive. Although factor Bb exhibits an 
apparent Km for plasminogen cleavage of 20 nM, it may be a relatively ineffective 
plasminogen activator, cleaving <0.8  mol of substrate plasminogen per mol of 
factor Bb per minute under the best experimental conditions to date (J. Sundsmo, 
unpublished data.). 
Many bacterial, cellular, viral, parasitic, and chemical agents may activate the 
alternative pathway of complement. The present findings raise the possibility 
that macrophage-derived factor B may participate locally in certain physiologic 
and pathologic immune responses. Whether several cell types are necessary to SUNDSMO ET AL.  319 
activate  and  assemble  complement proteinases  of the  leukocyte complement 
system (52) remains to be determined. 
Summary 
Factor B,  the complement alternative pathway serine proteinase, a  class III 
gene product of the major histocompatibility complex, is a  major constitutive 
secretion product  of mouse  mononuclear phagocytes.  This  glycoprotein was 
synthesized and secreted by macrophages as a doublet of Mr 90,000 and 93,000 
polypeptides  that  were immunoprecipitable  with  antibodies  raised  to  human 
serum factor B, and that were indistinguishable from plasma factor B by immu- 
noreactivity, peptide mapping, and molecular weight. Macrophage factor B was 
cleaved and activated to factor Bb- and Ba-like fragments by factor D and cobra 
venom factor. Some conversion of macrophage factor B to Bb-sized fragments 
occurred spontaneously in the conditioned culture medium after several hours. 
Factor  B  represented  ~0.5%  of newly synthesized protein  and  4-6%  of the 
secreted protein of resident peritoneal macrophages and macrophages elicited 
with thioglycollate broth, pyran copolymer, NalO4, bacillus Calmette-Guerin, or 
Corynebacterium  parvum.  We detected synthesis of factor B  immediately upon 
explanting these macrophages in culture; synthesis continued for several days in 
culture.  The  rate  of secretion of factor  B,  as  a  proportion  of total  protein 
secretion in culture, remained constant with time. By radioimmunoassay, factor 
B antigens accumulated in the 24-h macrophage-conditioned culture medium at 
2-10 nM, ~md was present in cell lysates at 4-8 nmol per 106 cells. We detected 
synthesis of factor B  in bone marrow-derived macrophages as early as 5  d  of 
culture. The P388D1  macrophage line synthesized factor B, but mouse L cells 
did not. In contrast, apolipoprotein E, another secreted protein of macrophages, 
was  secreted by  resident  and  thioglycollate-elicited macrophages but  not  by 
freshly  harvested  pyran  copolymer-activated macrophages.  Its  synthesis  was 
initiated at day 9 in culture of bone marrow-derived macrophages. These data 
support the classification of factor B as a constitutive biosynthetic' and secreted 
protein of immature and  mature macrophages in  various states of activation. 
Production of factor B was modulated by treatment of macrophages in vivo or 
in  culture  with  bacterial  lipopolysaccharide  endotoxin,  which  increased  the 
synthesis, secretion, and accumulation of factor B up to 11-fold. 
We thank Dr.  Michael J. Banda for his critical reading of the manuscript,  and William 
Keene for assistance with the photography. 
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